Cover Image
市場調查報告書

癌症免疫療法市場 (單株抗體、免疫查核點抑制劑 (PD-1/PD-L1及CTLA-4)、免疫系調整劑,及癌症疫苗) - 全球產業分析、規模、佔有率、成長、趨勢,及預測

Cancer Immunotherapy Market (Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

出版商 Transparency Market Research 商品編碼 410939
出版日期 內容資訊 英文 222 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症免疫療法市場 (單株抗體、免疫查核點抑制劑 (PD-1/PD-L1及CTLA-4)、免疫系調整劑,及癌症疫苗) - 全球產業分析、規模、佔有率、成長、趨勢,及預測 Cancer Immunotherapy Market (Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
出版日期: 2016年12月14日 內容資訊: 英文 222 Pages
簡介

本報告提供全球癌症免疫療法市場相關調查,市場趨勢,各終端用戶,各治療領域,各地區趨勢,SWOT分析,及打入市場的主要企業簡介等彙整資料。

第1章 序論

第2章 假設和調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
    • 市場定義
    • 產業的發展
  • 概要
  • 主要市場指標
    • 各治療
    • 各產品、治療領域
    • 各標的
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
    • 趨勢
  • 市場分析與預測
  • 全球供需方案
  • 波特五力分析
  • 價值鏈分析
  • 市場預測
  • 開發平台趨勢
  • 癌症病因
  • 償付方案及患者支援計劃概要

第5章 各治療

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • 單株抗體
    • 免疫查核點抑制劑
    • 免疫系調整劑
    • 癌症疫苗
    • 其他
  • 市場魅力度

第6章 各終端用戶市場分析與預測

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • 醫院
    • 門診外科中心
    • 癌症研究所
    • 診療所
  • 市場魅力度

第7章 各治療領域市場分析與預測

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • 肺癌
    • 大腸癌
    • 乳癌
    • 前列腺癌
    • 黑色素瘤
    • 血液癌症
    • 其他
  • 市場魅力度

第8章 各地區市場分析與預測

  • 主要調查結果
  • 方針和法律規章
  • 市場價值預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 市場魅力度

第9章 北美市場

第10章 歐洲市場

第11章 亞太地區市場

第12章 南美市場

第13章 中東、非洲市場

第14章 競爭環境

  • 主要企業:競爭矩陣
  • 各企業市場佔有率分析
  • 企業簡介
    • Amgen, Inc.
    • AstraZenca Plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F.Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc.
    • Janssen Biotech, Inc.
    • Merck & Co.
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi
    • Spectrum Pharmaceuticals, Inc.
    • 武田藥品工業株式會社
目錄

Title: Cancer Immunotherapy Market (Therapy Type - Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines; Therapeutic Areas - Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, and Blood Cancers; End Users - Hospitals, ASC's (Ambulatory Surgical Centers), and Cancer Research Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.

Global Cancer Immunotherapy Market: Overview

The growing incidences of cancer and a need to treat them is the key driver of the global immunotherapy market. The number of deaths occurring due to cancer is increasing every year and has therefore forced government bodies to take initiatives for the improvement of the health conditions of people, by investing heavily in research and development and enabling innovation and advancements in technology so as to offer improved treatments. This has pushed the growth of the global cancer immunotherapy therapy. As immunotherapy therapy has a higher success rate and proven efficiency over conventional treatment methods for cancer, its demand is higher and therefore, the market is expected to witness a remarkable growth over the coming years. The treatment pipeline looks promising and is thus, expected to ensure a healthy growth of the market.

The report offers forecasts of the overall cancer immunotherapy market over the global level as well as on regional levels. The estimated size of each of the segments and sub-segments has also been given in the report. Macroeconomic indicators, drivers, and restraints impacting the global cancer immunotherapy market have been included along with their impact on each region. Current challenges met by players in the cancer immunotherapy market have been elaborated on, thus giving a brief idea to readers and investors the problems they may encounter while investing in the competitive market.

Global Cancer Immunotherapy Market: Trends and Drivers

The global cancer immunotherapy market is expected to hold promising growth as there lies immense scope for improvement and development. The increasing number of clinical trials held particularly in immunotherapy is expected to boost the market's growth. With the recognition from various medical bodies as the foremost line of therapy over conventional chemotherapy, cancer immunotherapy is estimated to hold immense potential and growth opportunity in the coming years.

However, factors such as high attrition rates during product development phase are anticipated to restrict the growth of the market. Also, an overall lack of awareness about immunotherapy being a better treatment option will impede the growth of the market. The high cost of clinical trials poses a challenge for players in the market. With many types and subtypes of cancer, having a single mode of treatment method is impossible, increasing the attrition rates of new drugs and treatments. Only a handful of contenders in the pipeline pass through the phase III trials and the rest are considered to be inefficient. This is yet another challenge faced by players in the market.

Global Cancer Immunotherapy Market: Segmentation

On the basis of therapeutic area, the market is segmented into colorectal cancer, lung cancer, breast cancer, melanoma, prostate cancer, and blood cancer. By end users, the global cancer immunotherapy market is segmented into ASC's (ambulatory surgical centers), hospitals, clinics, and cancer research centers. Hospitals are expected to be the leading segment in the market. On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. Asia Pacific is poised to witness significant growth in the market.

Key Players Mentioned in this Report are:

The report provides studies key players operating in the market. Some of the key players in the global cancer immunotherapy market are: F.Hoffmann-La Roche Ltd., AstraZenca Plc, Eli Lilly and Company, Amgen, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline Plc., Novartis AG, Pfizer, Inc., Janssen Biotech, Inc., Merck & Co., Inc., Janssen Biotech, Inc., Merck & Co., Inc., Sanofi, Takeda Pharmaceuticals, and Spectrum Pharmaceuticals, Inc.

The report segments the global cancer immunotherapy market as:

By Geography:

  • North America
  • Asia Pacific
  • Europe
  • Rest of the World

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Cancer Immunotherapy Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Market Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Key Market Indicators
    • 4.3.1. Region/Country Specific
    • 4.3.2. Product/Therapeutic Area Specific
    • 4.3.3. Target Market Specific - Global Scenario
  • 4.4. Market Dynamics
    • 4.4.1. Drivers
    • 4.4.2. Restraints
    • 4.4.3. Opportunity
    • 4.4.4. Trends
  • 4.5. Global Cancer Immunotherapy Market Analysis and Forecasts, 2016-2024
    • 4.5.1. Market Revenue Projections (US$ Mn)
  • 4.6. Cancer Immunotherapy Market - Global Supply Demand Scenario
  • 4.7. Porter's Five Force Analysis
  • 4.8. Value Chain Analysis
    • 4.8.1. List of active market participants
      • 4.8.1.1. Manufacturers
      • 4.8.1.2. Distributors
    • 4.8.2. Forward - Backward Integration Scenario
  • 4.9. Market Outlook
  • 4.10. Pipeline Snapshot
  • 4.11. Cancer Epidemiology
  • 4.12. Reimbursement Scenario and Patient Support Programs Overview

5. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapy Type

  • 5.1. Introduction & Definition
  • 5.2. Key Findings / Developments
  • 5.3. Market Value Forecast By Therapy Type, 2016-2024
    • 5.3.1. Monoclonal Antibodies
    • 5.3.2. Immune Checkpoint Inhibitors
      • 5.3.2.1. PD-1/PD-L1
      • 5.3.2.2. CTLA-4
    • 5.3.3. Immune System Modulators
    • 5.3.4. Cancer Vaccines
    • 5.3.5. Others
  • 5.4. Market Attractiveness By Therapy

6. Global Cancer Immunotherapy Market Analysis and Forecasts, By End User

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By End User, 2016-2024
    • 6.3.1. Hospitals
    • 6.3.2. ASC's
    • 6.3.3. Cancer Research Institutes
    • 6.3.4. Clinics
  • 6.4. Market Attractiveness By End User

7. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapeutic Area

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Therapeutic Area, 2016-2024
    • 7.3.1. Lung Cancer
    • 7.3.2. Colorectal Cancer
    • 7.3.3. Breast Cancer
    • 7.3.4. Prostate Cancer
    • 7.3.5. Melanoma
    • 7.3.6. Blood Cancers
    • 7.3.7. Others
  • 7.4. Market Attractiveness By Therapeutic Area

8. Global Cancer Immunotherapy Market Analysis and Forecasts, By Region

  • 8.1. Key Findings
  • 8.2. Policies and Regulations
  • 8.3. Market Value Forecast By Region
    • 8.3.1. North America
    • 8.3.2. Europe
    • 8.3.3. Asia Pacific
    • 8.3.4. Latin America
    • 8.3.5. Middle East and Africa
  • 8.4. Market Attractiveness By Region

9. North America Cancer Immunotherapy Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
    • 9.1.2. Policies and Regulations
  • 9.2. Market Value Forecast By Therapy Type, 2016-2024
    • 9.2.1. Monoclonal Antibodies
    • 9.2.2. Immune Checkpoint Inhibitors
      • 9.2.2.1. PD-1/PD-L1
      • 9.2.2.2. CTLA-4
    • 9.2.3. Immune System Modulators
    • 9.2.4. Cancer Vaccines
    • 9.2.5. Others
  • 9.3. Market Value Forecast By End User, 2016-2024
    • 9.3.1. Hospitals
    • 9.3.2. ASC's
    • 9.3.3. Cancer Research Institutes
    • 9.3.4. Clinics
  • 9.4. Market Value Forecast By Therapeutic Area, 2016-2024
    • 9.4.1. Lung Cancer
    • 9.4.2. Colorectal Cancer
    • 9.4.3. Breast Cancer
    • 9.4.4. Prostate Cancer
    • 9.4.5. Melanoma
    • 9.4.6. Blood Cancer
    • 9.4.7. Others
  • 9.5. Market Value Forecast By Country, 2016-2024
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Therapy Type
    • 9.6.2. By End User
    • 9.6.3. By Therapeutic Area
    • 9.6.4. By Country

10. Europe Cancer Immunotherapy Market Analysis and Forecast

  • 10.1.Introduction
    • 10.1.1. Key Findings
    • 10.1.2. Policies and Regulations
  • 10.2.Market Value Forecast By Therapy Type, 2016-2024
    • 10.2.1. Monoclonal Antibodies
    • 10.2.2. Immune Checkpoint Inhibitors
      • 10.2.2.1. PD-1/PD-L1
      • 10.2.2.2. CTLA-4
    • 10.2.3. Immune System Modulators
    • 10.2.4. Cancer Vaccines
    • 10.2.5. Others
  • 10.3.Market Value Forecast By End User, 2016-2024
    • 10.3.1. Hospitals
    • 10.3.2. ASC's
    • 10.3.3. Cancer Research Institutes
    • 10.3.4. Clinics
  • 10.4.Market Value Forecast By Therapeutic Area, 2016-2024
    • 10.4.1. Lung Cancer
    • 10.4.2. Colorectal Cancer
    • 10.4.3. Breast Cancer
    • 10.4.4. Prostate Cancer
    • 10.4.5. Melanoma
    • 10.4.6. Blood Cancer
    • 10.4.7. Others
  • 10.5.Market Value Forecast By Country, 2016-2024
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Spain
    • 10.5.5. Italy
    • 10.5.6. Rest of Europe
  • 10.6.Market Attractiveness Analysis
    • 10.6.1. By Therapy Type
    • 10.6.2. By End User
    • 10.6.3. By Therapeutic Area
    • 10.6.4. By Country

11. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Key Findings
    • 11.1.2. Policies and Regulations
  • 11.2.Market Value Forecast By Therapy Type, 2016-2024
    • 11.2.1. Monoclonal Antibodies
    • 11.2.2. Immune Checkpoint Inhibitors
      • 11.2.2.1. PD-1/PD-L1
      • 11.2.2.2. CTLA-4
    • 11.2.3. Immune System Modulators
    • 11.2.4. Cancer Vaccines
    • 11.2.5. Others
  • 11.3.Market Value Forecast By End User, 2016-2024
    • 11.3.1. Hospitals
    • 11.3.2. ASC's
    • 11.3.3. Cancer Research Institutes
    • 11.3.4. Clinics
  • 11.4.Market Value Forecast By Therapeutic Area, 2016-2024
    • 11.4.1. Lung Cancer
    • 11.4.2. Colorectal Cancer
    • 11.4.3. Breast Cancer
    • 11.4.4. Prostate Cancer
    • 11.4.5. Melanoma
    • 11.4.6. Blood Cancer
    • 11.4.7. Others
  • 11.5.Market Value Forecast By Country, 2016-2024
    • 11.5.1. Japan
    • 11.5.2. China
    • 11.5.3. India
    • 11.5.4. Australia
    • 11.5.5. New Zealand
    • 11.5.6. Rest of APAC
  • 11.6.Market Attractiveness Analysis
    • 11.6.1. By Therapy Type
    • 11.6.2. By End User
    • 11.6.3. By Therapeutic Area
    • 11.6.4. By Country

12. Latin America Cancer Immunotherapy Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Key Findings
    • 12.1.2. Policies and Regulations
  • 12.2.Market Value Forecast By Therapy Type, 2016-2024
    • 12.2.1. Monoclonal Antibodies
    • 12.2.2. Immune Checkpoint Inhibitors
      • 12.2.2.1. PD-1/PD-L1
      • 12.2.2.2. CTLA-4
    • 12.2.3. Immune System Modulators
    • 12.2.4. Cancer Vaccines
    • 12.2.5. Others
  • 12.3.Market Value Forecast By End User, 2016-2024
    • 12.3.1. Hospitals
    • 12.3.2. ASC's
    • 12.3.3. Cancer Research Institutes
    • 12.3.4. Clinics
  • 12.4.Market Value Forecast By Therapeutic Area, 2016-2024
    • 12.4.1. Lung Cancer
    • 12.4.2. Colorectal Cancer
    • 12.4.3. Breast Cancer
    • 12.4.4. Prostate Cancer
    • 12.4.5. Melanoma
    • 12.4.6. Blood Cancer
    • 12.4.7. Others
  • 12.5.Market Value Forecast By Country, 2016-2024
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6.Market Attractiveness Analysis
    • 12.6.1. By Therapy Type
    • 12.6.2. By End User
    • 12.6.3. By Therapeutic Area
    • 12.6.4. By Country

13. Middle East and Africa Cancer Immunotherapy Market Analysis and Forecast

  • 13.1.Introduction
    • 13.1.1. Key Findings
    • 13.1.2. Policies and Regulations
  • 13.2.Market Value Forecast By Therapy Type, 2016-2024
    • 13.2.1. Monoclonal Antibodies
    • 13.2.2. Immune Checkpoint Inhibitors
      • 13.2.2.1. PD-1/PD-L1
      • 13.2.2.2. CTLA-4
    • 13.2.3. Immune System Modulators
    • 13.2.4. Cancer Vaccines
    • 13.2.5. Others
  • 13.3.Market Value Forecast By End User, 2016-2024
    • 13.3.1. Hospitals
    • 13.3.2. ASC's
    • 13.3.3. Cancer Research Institutes
    • 13.3.4. Clinics
  • 13.4.Market Value Forecast By Therapeutic Area, 2016-2024
    • 13.4.1. Lung Cancer
    • 13.4.2. Colorectal Cancer
    • 13.4.3. Breast Cancer
    • 13.4.4. Prostate Cancer
    • 13.4.5. Melanoma
    • 13.4.6. Blood Cancer
    • 13.4.7. Others
  • 13.5.Market Value Forecast By Country, 2016-2024
    • 13.5.1. Saudi Arabia
    • 13.5.2. UAE
    • 13.5.3. South Africa
    • 13.5.4. Rest of MEA
  • 13.6.Market Attractiveness Analysis
    • 13.6.1. By Therapy Type
    • 13.6.2. By End User
    • 13.6.3. By Therapeutic Area
    • 13.6.4. By Country

14. Competition Landscape

  • 14.1.Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2.Market Share Analysis By Company (2015)
  • 14.3.Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 14.3.1. Amgen, Inc.
      • 14.3.1.1. Overview
      • 14.3.1.2. Financials
      • 14.3.1.3. Recent Developments
      • 14.3.1.4. Strategy
    • 14.3.2. AstraZenca Plc
      • 14.3.2.1. Overview
      • 14.3.2.2. Financials
      • 14.3.2.3. Recent Developments
      • 14.3.2.4. Strategy
    • 14.3.3. Bristol-Myers Squibb Company
      • 14.3.3.1. Overview
      • 14.3.3.2. Financials
      • 14.3.3.3. Recent Developments
      • 14.3.3.4. Strategy
    • 14.3.4. Eli Lilly and Company
      • 14.3.4.1. Overview
      • 14.3.4.2. Financials
      • 14.3.4.3. Recent Developments
      • 14.3.4.4. Strategy
    • 14.3.5. F.Hoffmann-La Roche Ltd.
      • 14.3.5.1. Overview
      • 14.3.5.2. Financials
      • 14.3.5.3. Recent Developments
      • 14.3.5.4. Strategy
    • 14.3.6. GlaxoSmithKline Plc.
      • 14.3.6.1. Overview
      • 14.3.6.2. Financials
      • 14.3.6.3. Recent Developments
      • 14.3.6.4. Strategy
    • 14.3.7. Janssen Biotech, Inc.
      • 14.3.7.1. Overview
      • 14.3.7.2. Financials
      • 14.3.7.3. Recent Developments
      • 14.3.7.4. Strategy
    • 14.3.8. Merck & Co.
      • 14.3.8.1. Overview
      • 14.3.8.2. Financials
      • 14.3.8.3. Recent Developments
      • 14.3.8.4. Strategy
    • 14.3.9. Novartis AG
      • 14.3.9.1. Overview
      • 14.3.9.2. Financials
      • 14.3.9.3. Recent Developments
      • 14.3.9.4. Strategy
    • 14.3.10. Pfizer, Inc.
      • 14.3.10.1. Overview
      • 14.3.10.2. Financials
      • 14.3.10.3. Recent Developments
      • 14.3.10.4. Strategy
    • 14.3.11. Sanofi
      • 14.3.11.1. Overview
      • 14.3.11.2. Financials
      • 14.3.11.3. Recent Developments
      • 14.3.11.4. Strategy
    • 14.3.12. Spectrum Pharmaceuticals, Inc.
      • 14.3.12.1. Overview
      • 14.3.12.2. Financials
      • 14.3.12.3. Recent Developments
      • 14.3.12.4. Strategy
    • 14.3.13. Takeda Pharmaceuticals
      • 14.3.13.1. Overview
      • 14.3.13.2. Financials
      • 14.3.13.3. Recent Developments
      • 14.3.13.4. Strategy

List of Figures

  • Figure 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2015-2024
  • Figure 2: Global Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
  • Figure 3: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Monoclonal Antibodies, 2016-2024
  • Figure 4: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune Checkpoint Inhibitors, 2016-2024
  • Figure 5: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune System Modulators, 2016-2024
  • Figure 6: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Vaccines, 2016-2024
  • Figure 7: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Others, 2016-2024
  • Figure 8: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type
  • Figure 9: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By PD-1/PD-L1 Type, 2016-2024
  • Figure 10: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By CTLA-4 Type, 2016-2024
  • Figure 11: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type (Immune Checkpoint Inhibitors)
  • Figure 12: Global Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
  • Figure 13: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area
  • Figure 14: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Lung Cancer, 2016-2024
  • Figure 15: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Colorectal Cancer, 2016-2024
  • Figure 16: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Breast Cancer, 2016-2024
  • Figure 17: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Prostate Cancer, 2016-2024
  • Figure 18: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Melanoma, 2016-2024
  • Figure 19: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Blood Cancers, 2016-2024
  • Figure 20: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Other Cancers, 2016-2024
  • Figure 21: Global Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
  • Figure 22: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Hospitals, 2016-2024
  • Figure 23: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By ASC's, 2016-2024
  • Figure 24: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Research Institutes, 2016-2024
  • Figure 25: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Clinics, 2016-2024
  • Figure 26: Global Cancer Immunotherapy Market Attractiveness Analysis, by End-User
  • Figure 27: Global Cancer Immunotherapy Market Value Share Analysis, by Region, 2016 and 2024
  • Figure 28: Global Cancer Immunotherapy Market Attractiveness Analysis, by Region
  • Figure 29: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 30: North America Cancer Immunotherapy Market Attractiveness Analysis By Country
  • Figure 31: North America Market Value Share Analysis, by Therapy Type, 2016 and 2024
  • Figure 32: North America Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
  • Figure 33: North America Market Value Share Analysis, by End-User, 2016 and 2024
  • Figure 34: North America Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 35: U.S. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 36: U.S. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 37: Canada Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 38: Canada Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 39: North America Cancer Immunotherapy Market Attractiveness by Therapy Type
  • Figure 40: North America Cancer Immunotherapy Market Attractiveness by Therapeutic Area
  • Figure 41: North America Cancer Immunotherapy Market Attractiveness by End-User
  • Figure 42: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 43: Europe Cancer Immunotherapy Market Attractiveness Analysis by Country
  • Figure 44: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
  • Figure 45: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
  • Figure 46: Europe Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
  • Figure 47: Europe Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 48: Germany Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 49: Germany Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 50: U.K. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 51: U.K. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 52: France Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 53: France Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 54: Spain Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 55: Spain Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 56: Italy Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 57: Italy Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 58: Rest of Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 59: Rest of Europe Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 60: Europe Cancer Immunotherapy Market Attractiveness by Therapy Type
  • Figure 61: Europe Cancer Immunotherapy Market Attractiveness by Therapeutic Area
  • Figure 62: Europe Cancer Immunotherapy Market Attractiveness by End-User
  • Figure 63: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 64: Asia Pacific Cancer Immunotherapy Market Attractiveness Analysis, By Country
  • Figure 65: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
  • Figure 66: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
  • Figure 67: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
  • Figure 68: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 69: Japan Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 70: Japan Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 71: China Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 72: China Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 73: India Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 74: India Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 75: Australia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 76: Australia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 77: New Zealand Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 78: New Zealand Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 79: Rest of Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 80: Rest of Asia Pacific Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 81: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapy Type
  • Figure 82: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapeutic Area
  • Figure 83: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User
  • Figure 84: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User
  • Figure 85: Latin America Cancer Immunotherapy Market Attractiveness Analysis by Country
  • Figure 86: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
  • Figure 87: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
  • Figure 88: Latin America Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
  • Figure 89: Latin America Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 90: Brazil Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 91: Brazil Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 92: Mexico Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 93: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 94: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 95: Rest of Latin America Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 96: Latin America Cancer Immunotherapy Market Attractiveness by Therapy Type
  • Figure 97: Latin America Cancer Immunotherapy Market Attractiveness by Therapeutic Area
  • Figure 98: Latin America Cancer Immunotherapy Market Attractiveness by End-User
  • Figure 99: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 100: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis by Country
  • Figure 101: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
  • Figure 102: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
  • Figure 103: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
  • Figure 104: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
  • Figure 105: Saudi Arabia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 106: Saudi Arabia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 107: UAE Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 108: UAE Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 109: RSA Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 110: RSA Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 111: Rest of Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 112: Rest of Middle East & Africa Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016-2024
  • Figure 113: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapy Type
  • Figure 114: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapeutic Area
  • Figure 115: Middle East & Africa Cancer Immunotherapy Market Attractiveness by End-User

List of Tables

  • Table 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016-2024
  • Table 2: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, By Therapy Type (Immune Checkpoint Inhibitors), 2016-2024
  • Table 3: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016-2024
  • Table 4: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016-2024
  • Table 5: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Region, 2016-2024
  • Table 6: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016-2024
  • Table 7: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016-2024
  • Table 8: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016-2024
  • Table 9: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016-2024
  • Table 10: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 11: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016-2024
  • Table 12: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016-2024
  • Table 13: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016-2024
  • Table 14: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016-2024
  • Table 15: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 16: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 17: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016-2024
  • Table 18: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016-2024
  • Table 19: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016-2024
  • Table 20: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016-2024
  • Table 21: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 22: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016-2024
  • Table 23: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016-2024
  • Table 24: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016-2024
  • Table 25: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016-2024
  • Table 26: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 27: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016-2024
  • Table 28: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016-2024
  • Table 29: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016-2024
  • Table 30: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016-2024
Back to Top